ESKAPE 病原体中的抗微生物药物耐药性。
Antimicrobial Resistance in ESKAPE Pathogens.
机构信息
School of Chemistry and Molecular Biosciences, The University of Queensland, QLD, Australia.
Australian Infectious Diseases Research Centre, The University of Queensland, QLD, Australia.
出版信息
Clin Microbiol Rev. 2020 May 13;33(3). doi: 10.1128/CMR.00181-19. Print 2020 Jun 17.
Abstract
Antimicrobial-resistant ESKAPE ( , , , , , and species) pathogens represent a global threat to human health. The acquisition of antimicrobial resistance genes by ESKAPE pathogens has reduced the treatment options for serious infections, increased the burden of disease, and increased death rates due to treatment failure and requires a coordinated global response for antimicrobial resistance surveillance. This looming health threat has restimulated interest in the development of new antimicrobial therapies, has demanded the need for better patient care, and has facilitated heightened governance over stewardship practices.
摘要
耐抗菌药物的 ESKAPE（肠杆菌科、金黄色葡萄球菌、肺炎克雷伯菌、鲍曼不动杆菌、铜绿假单胞菌和屎肠球菌）病原体对人类健康构成了全球性威胁。ESKAPE 病原体获得抗微生物耐药基因，减少了严重感染的治疗选择，增加了疾病负担，并因治疗失败而导致死亡率上升，需要采取协调一致的全球对策来进行抗微生物药物耐药性监测。这种迫在眉睫的健康威胁重新激发了人们对抗微生物治疗新疗法的开发兴趣，要求更好地护理患者，并促进加强对抗微生物药物管理实践的治理。
相似文献
1
Antimicrobial Resistance in ESKAPE Pathogens.ESKAPE 病原体中的抗微生物药物耐药性。
Clin Microbiol Rev. 2020 May 13;33(3). doi: 10.1128/CMR.00181-19. Print 2020 Jun 17.
2
Global priority pathogens: virulence, antimicrobial resistance and prospective treatment options.全球优先病原体：毒力、抗微生物药物耐药性和预期治疗选择。
Future Microbiol. 2020 May;15:649-677. doi: 10.2217/fmb-2019-0333. Epub 2020 Jun 4.
3
Clinical relevance of the ESKAPE pathogens.ESKAPE 病原体的临床相关性。
Expert Rev Anti Infect Ther. 2013 Mar;11(3):297-308. doi: 10.1586/eri.13.12.
4
Novel antimicrobial agents for combating antibiotic-resistant bacteria.用于对抗抗生素耐药细菌的新型抗菌剂。
Adv Drug Deliv Rev. 2022 Aug;187:114378. doi: 10.1016/j.addr.2022.114378. Epub 2022 Jun 4.
5
ESKAPE pathogens: antimicrobial resistance, epidemiology, clinical impact and therapeutics.ESKAPE 病原体：抗微生物药物耐药性、流行病学、临床影响和治疗学。
Nat Rev Microbiol. 2024 Oct;22(10):598-616. doi: 10.1038/s41579-024-01054-w. Epub 2024 Jun 3.
6
Prevalence of Antibiotic Resistance of ESKAPE Pathogens Over Five Years in an Infectious Diseases Hospital from South-East of Romania.罗马尼亚东南部一家传染病医院五年内ESKAPE病原体的抗生素耐药性流行情况
Infect Drug Resist. 2021 Jun 24;14:2369-2378. doi: 10.2147/IDR.S312231. eCollection 2021.
7
ESKAPE in China: epidemiology and characteristics of antibiotic resistance.中国的 ESKAPE：耐药性的流行病学和特征。
Emerg Microbes Infect. 2024 Dec;13(1):2317915. doi: 10.1080/22221751.2024.2317915. Epub 2024 Feb 23.
8
A Whole-Cell Screen Identifies Small Bioactives That Synergize with Polymyxin and Exhibit Antimicrobial Activities against Multidrug-Resistant Bacteria.全细胞筛选发现与多粘菌素协同作用并具有抗多重耐药菌活性的小分子生物活性物质。
Antimicrob Agents Chemother. 2020 Feb 21;64(3). doi: 10.1128/AAC.01677-19.
9
ESKAPEing the labyrinth of antibacterial discovery.逃出抗菌药物发现的迷宫。
Nat Rev Drug Discov. 2015 Aug;14(8):529-42. doi: 10.1038/nrd4572. Epub 2015 Jul 3.
10
Dramatic increase in antimicrobial resistance in ESKAPE clinical isolates over the 2010-2020 decade in India.在过去的十年（2010 年至 2020 年），印度 ESKAPE 临床分离株的抗菌药物耐药性急剧增加。
Int J Antimicrob Agents. 2024 May;63(5):107125. doi: 10.1016/j.ijantimicag.2024.107125. Epub 2024 Feb 29.
引用本文的文献
1
In Vitro synergy of Farnesyltransferase inhibitors in combination with colistin against ESKAPE bacteria.法尼基转移酶抑制剂与黏菌素联合对ESKAPE细菌的体外协同作用
PLoS One. 2025 Sep 5;20(9):e0331440. doi: 10.1371/journal.pone.0331440. eCollection 2025.
2
A streamlined method to determine the antibiotic resistance of plaque-forming predatory bacteria.一种用于确定形成菌斑的捕食性细菌抗生素抗性的简化方法。
Front Microbiol. 2025 Aug 19;16:1582371. doi: 10.3389/fmicb.2025.1582371. eCollection 2025.
3
Plastispheres as reservoirs of antimicrobial resistance: Insights from metagenomic analyses across aquatic environments.作为抗菌素耐药性储存库的塑料球：来自对水生环境宏基因组分析的见解
PLoS One. 2025 Sep 3;20(9):e0330754. doi: 10.1371/journal.pone.0330754. eCollection 2025.
4
Antimicrobial Nanoparticles Against Superbugs: Mechanistic Insights, Biomedical Applications, and Translational Frontiers.抗超级细菌的抗菌纳米颗粒：作用机制洞察、生物医学应用及转化前沿
Pharmaceuticals (Basel). 2025 Aug 13;18(8):1195. doi: 10.3390/ph18081195.
5
Optimization and Characterization of Bioactive Metabolites from Cave-Derived C1.洞穴来源的C1生物活性代谢产物的优化与表征
Biomolecules. 2025 Jul 24;15(8):1071. doi: 10.3390/biom15081071.
6
Determination of the prevalence of hypervirulent Klebsiella pneumoniae strains in Northeast Iran, Mashhad.伊朗东北部马什哈德高毒力肺炎克雷伯菌菌株流行率的测定
Sci Rep. 2025 Aug 27;15(1):31579. doi: 10.1038/s41598-025-16969-4.
7
Discovery of New Everninomicin Analogs from a Marine-Derived sp. by Metabolomics and Genomics Approaches.通过代谢组学和基因组学方法从海洋来源的链霉菌中发现新的埃博霉素类似物
Mar Drugs. 2025 Jul 31;23(8):316. doi: 10.3390/md23080316.
8
Synergistic action between peptide-neomycin conjugates and polymyxin B against multidrug-resistant gram-negative pathogens.肽-新霉素偶联物与多粘菌素B对多重耐药革兰氏阴性病原体的协同作用。
Front Microbiol. 2025 Aug 7;16:1605813. doi: 10.3389/fmicb.2025.1605813. eCollection 2025.
9
2‑Aminoimidazole-benzimidazole Conjugates Potentiate the Gram-Positive Selective Antibiotic Clarithromycin against .2-氨基咪唑-苯并咪唑缀合物增强革兰氏阳性选择性抗生素克拉霉素对……的作用 。 （原文句末不完整）
ACS Med Chem Lett. 2025 Jul 1;16(8):1562-1568. doi: 10.1021/acsmedchemlett.5c00201. eCollection 2025 Aug 14.
10
Antibacterial activity and mechanism of naphthoquine phosphate against ceftazidime-resistant via cell membrane disruption and ROS induction.磷酸萘喹通过破坏细胞膜和诱导活性氧对耐头孢他啶菌的抗菌活性及机制
Front Microbiol. 2025 Aug 4;16:1603462. doi: 10.3389/fmicb.2025.1603462. eCollection 2025.
本文引用的文献
1
Persistence of Immune Responses Through 36 Months in Healthy Adults After Vaccination With a Novel 4-Antigen Vaccine (SA4Ag).新型四抗原疫苗（SA4Ag）接种后，健康成年人免疫反应持续36个月。
Open Forum Infect Dis. 2019 Dec 24;7(1):ofz532. doi: 10.1093/ofid/ofz532. eCollection 2020 Jan.
2
Low prevalence of livestock-associated methicillin-resistant Staphylococcus aureus clonal complex 398 and mecC MRSA among human isolates in North-West England.英格兰西北部人类分离株中低流行的与牲畜相关的耐甲氧西林金黄色葡萄球菌克隆复合体 398 和 mecC 型耐甲氧西林金黄色葡萄球菌。
J Appl Microbiol. 2020 Jun;128(6):1785-1792. doi: 10.1111/jam.14578. Epub 2020 Jan 24.
3
Effect of tolerance on the evolution of antibiotic resistance under drug combinations.耐约性对联合用药下抗生素耐药性进化的影响。
Science. 2020 Jan 10;367(6474):200-204. doi: 10.1126/science.aay3041.
4
The global preclinical antibacterial pipeline.全球临床前抗菌药物研发管线。
Nat Rev Microbiol. 2020 May;18(5):275-285. doi: 10.1038/s41579-019-0288-0. Epub 2019 Nov 19.
5
Cefiderocol: A Novel Siderophore Cephalosporin Defeating Carbapenem-resistant Pathogens.头孢地尔罗：一种新型的铁载体头孢菌素，可攻克碳青霉烯类耐药病原体。
Clin Infect Dis. 2019 Nov 13;69(Suppl 7):S519-S520. doi: 10.1093/cid/ciz823.
6
The Global Ascendency of OXA-48-Type Carbapenemases.OXA-48 型碳青霉烯酶的全球优势地位
Clin Microbiol Rev. 2019 Nov 13;33(1). doi: 10.1128/CMR.00102-19. Print 2019 Dec 18.
7
Becomes Susceptible to Polymyxin B and Colistin in the Presence of PBT2.在存在PBT2的情况下，对多粘菌素B和黏菌素变得敏感。
ACS Infect Dis. 2020 Jan 10;6(1):50-55. doi: 10.1021/acsinfecdis.9b00307. Epub 2019 Nov 11.
8
The role of new β-lactamase inhibitors in gram-negative infections.新型β-内酰胺酶抑制剂在革兰氏阴性感染中的作用。
Curr Opin Infect Dis. 2019 Dec;32(6):638-646. doi: 10.1097/QCO.0000000000000600.
9
Oral Lefamulin vs Moxifloxacin for Early Clinical Response Among Adults With Community-Acquired Bacterial Pneumonia: The LEAP 2 Randomized Clinical Trial.口服来法莫林与莫西沙星治疗社区获得性细菌性肺炎成人患者的早期临床反应：LEAP 2随机临床试验
JAMA. 2019 Nov 5;322(17):1661-1671. doi: 10.1001/jama.2019.15468.
10
Ceftobiprole: drug evaluation and place in therapy.头孢托罗：药物评估和治疗地位。
Expert Rev Anti Infect Ther. 2019 Sep;17(9):689-698. doi: 10.1080/14787210.2019.1667229. Epub 2019 Sep 25.
Zotero 插件